Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Avidity Biosciences, Inc. (RNA) Receivables - Other (2024 - 2025)

Avidity Biosciences' Receivables - Other history spans 2 years, with the latest figure at $12.4 million for Q4 2025.

  • For Q4 2025, Receivables - Other rose 31.67% year-over-year to $12.4 million; the TTM value through Dec 2025 reached $12.4 million, up 31.67%, while the annual FY2025 figure was $12.4 million, 31.67% up from the prior year.
  • Receivables - Other reached $12.4 million in Q4 2025 per RNA's latest filing, down from $15.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $15.0 million in Q3 2025 to a low of $8.5 million in Q2 2025.